Skip to main content
. 2021 Aug 4:NEJMoa2109682. doi: 10.1056/NEJMoa2109682

Table 3. Adverse Events.*.

Event REGEN-COV
(N=1311)
Placebo
(N=1306)
number of participants (percent)
Symptomatic Covid-19 15 (1.1) 112 (8.6)
Asymptomatic Covid-19 54 (4.1) 108 (8.3)
Headache 24 (1.8) 46 (3.5)
Injection-site reaction 55 (4.2) 19 (1.5)
*

Shown are the adverse events that occurred in at least 2% of the participants, regardless of the participants’ SARS-CoV-2 serologic status at baseline.